American Vanguard (AVD) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
17 Nov, 2025Executive summary
Adjusted EBITDA rose to $8.2 million from $1.8 million year-over-year, a 350%+ increase, driven by operational improvements and cost controls.
Gross profit margin improved by 300 basis points to 29% from 15% year-over-year, reflecting manufacturing optimization and lower costs.
Net sales for Q3 2025 were $119 million, up 1% year-over-year, with domestic sales up 8% and international sales down 6%.
Net loss narrowed to $12.4 million from $25.7 million in the prior year quarter; EPS improved to $(0.43) from $(0.91).
Transformation activities are now managed internally, with related spend reduced by nearly $7 million year-over-year.
Financial highlights
Q3 2025 net sales were $119 million (+1% YoY); gross profit was $34.2 million, nearly doubling from $17.3 million in Q3 2024.
Gross profit margin increased to 29% from 15% year-over-year; adjusted EBITDA margin improved to 7% from 1%.
Operating expenses decreased by 11% for the quarter and 14% year-to-date, with research and product development costs down $5.5 million.
Net debt reduced by $2 million year-over-year; inventory reduced by $47 million.
Q3 net loss was $12.4 million; nine months net loss was $21.7 million, improved from $35.9 million loss in 2024.
Outlook and guidance
Full-year 2025 adjusted EBITDA guidance maintained at $40 million-$44 million; net sales forecast at $520 million-$535 million.
Management expects Q4 to be the strongest quarter, with material free cash flow anticipated for debt reduction.
CapEx expected at $5 million-$6 million for 2025, with most free cash flow to be used for debt paydown.
Company aims to reduce leverage ratio below 3x by next year, supporting refinancing efforts.
Further gross profit margin improvement is expected due to ongoing efficiency initiatives.
Latest events from American Vanguard
- 2025 margins improved and losses narrowed; 2026 targets higher EBITDA and growth from new products.AVD
Q4 202516 Mar 2026 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025 - Adjusted EBITDA nearly doubled and gross margin hit a five-quarter high as net loss narrowed.AVD
Q2 20257 Aug 2025